Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heart Failure Polypill to Improve Outcomes at a Safety Net Hospital
NCT06029712Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Feb 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of heart failure polypill in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Measured Adherence to GDMT by Pill Count at 8 weeks. Started Feb 2024; status: completed.
02
Drugs
heart failure polypill
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT06029712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06029712.